Correction, November 4, 2026: An earlier version of this article called LSD the most advanced psychedelic in depression and said Definium’s program was ahead of the psilocybin programs. Compass Pathways had reported two positive Phase 3 trials in treatment-resistant depression and had a rolling NDA submission under way (company filing of May 13, 2026); Definium had reported one of two Phase 3 depression trials. The dek also credited the trial design with taking aim at the field’s methodological problem without saying that the 2:1:2 design belongs to Ascend, which has not reported; Emerge compared 100 micrograms with placebo alone. The headline, dek and passages have been revised.
The largest psychedelic catalyst in months is a positive pivotal Phase 3 readout in depression, and the molecule is LSD. Definium Therapeutics, the company formerly known as MindMed, reported positive topline results from Emerge, its Phase 3 trial of DT120, an orally disintegrating tablet of lysergide, or LSD, in major depressive disorder. The company reported that, at Week 6, the 100-microgram dose lowered the Montgomery-Åsberg Depression Rating Scale score by 13.3 points against 5.2 for placebo, a difference of 8.1 points, in a trial of 149 participants; the difference at Week 12 was 7.3 points. For reference, Compass’s two Phase 3 trials of psilocybin in treatment-resistant depression separated the 25 mg dose from their comparators by 3.6 and 3.8 points at Week 6, in a different population and design, so the comparison is a guide, not a ranking. The market read it as a significant derisking event, sending the stock up roughly 53 percent to a 52-week high, and the company moved immediately to raise capital on the strength of it.
What DT120 actually is
DT120 is lysergide, LSD, reformulated. It is the compound previously designated MM120 under MindMed, which rebranded to Definium Therapeutics. Pharmacologically it is an ergoline classic psychedelic that acts as a partial agonist at serotonin receptors, delivered here as a fast-dissolve oral tablet engineered for quicker, more consistent onset. The new-generation framing around it should not obscure the basic fact: the active ingredient is one of the oldest and most thoroughly studied psychedelics in existence, and it now has positive pivotal data in depression.
The scope is the story
This is not a single trial. Definium has assembled a multi-indication registrational program around lysergide. There are two pivotal Phase 3 trials in major depression, Emerge, now reported positive, and Ascend, which is enrolling. There are two Phase 3 trials in generalized anxiety disorder, Voyage and Panorama, with readouts expected in the third quarter of 2026. And a PTSD trial, Haven, is planned for 2027. The anxiety program carries an FDA Breakthrough Therapy designation, granted to the compound in March 2024, and the company positions it as potentially the first new GAD drug since 2007, a real claim given how stagnant anxiety pharmacology has been.
That breadth, not regulatory stage, is what distinguishes the program. On stage, Compass Pathways’ psilocybin is ahead: two positive Phase 3 trials in treatment-resistant depression and a rolling NDA submission under way as of May 13, 2026. Definium has reported one of its two depression trials and describes itself as advancing toward FDA submission. Helus Pharma’s HLP003 (formerly Cybin’s CYB003), a deuterated psilocin, has only just entered Phase 3 recruitment in major depression. Definium now has positive Phase 3 depression data in hand for LSD, the molecule almost no one expected to get this far.
The design is the part to watch
The most important technical feature of the program is how it handles functional unblinding, the problem that has shadowed every psychedelic trial. When patients and raters can tell who received an active psychedelic, that knowledge inflates the apparent treatment effect, and critics have argued that much of the measured benefit in psychedelic studies is expectancy rather than drug. The Ascend Phase 3 confronts this directly with a 2:1:2 randomization to 100 micrograms, 50 micrograms, or placebo, where the low 50-microgram arm exists specifically to blur patients’ ability to identify which condition they are in. It is an active-comparator approach to blinding, and the company argues that its Phase 2b anxiety data already demonstrated the drug’s effect was not attributable to functional unblinding.
This is a direct industry attempt to answer the field’s central methodological criticism. The desk has tracked the unblinding problem across the psilocybin trials and its hardware analog, the sham-response problem, in neuromodulation. Here a company has built one of its two depression trials around a design intended to defeat it; Emerge, the trial that has read out, compared 100 micrograms with placebo alone. Whether that design convinces the FDA that the effect is real rather than expectancy is one of the two questions that will decide the program’s fate.
The caveats, which are substantial
A positive topline is a press release, not a dataset. It means the company states the primary endpoint was met, and the effect sizes above are the company’s. The full dataset, the safety profile, the durability curves, and peer review are all still to come, and FDA review is a separate gate that positive-looking psychedelic programs have failed before, as the rejection of the MDMA application in 2024 demonstrated.
The unblinding fix is a claim to scrutinize, not to accept. A 50-microgram dose of LSD is still an active dose, and whether it genuinely prevents patients from knowing they received a psychedelic, and whether regulators agree the measured effect is not unblinding-driven, remains unresolved and central.
The duration problem is acute for this molecule. LSD’s acute effects last roughly eight to twelve hours, longer than psilocybin’s six to eight and far longer than DMT’s minutes. The desk has repeatedly identified the supervised-session length as the core economic obstacle to psychedelic therapy, and the reason developers engineer shorter-acting molecules. An orally disintegrating tablet speeds onset but does nothing to shorten the trip. So Definium is carrying a molecule whose acute effects last longer than psilocybin’s, a bet that efficacy and single-dose durability will outweigh the cost of a daylong supervised administration. That tension is unresolved, and it is the second question that will decide whether the program becomes a usable medicine.
LSD is also a Schedule I substance. Approval would require rescheduling, a risk-management program, and the supervised-administration infrastructure, and it lands squarely in the federal-state and governance complexity the desk has covered. Approval is necessary but not sufficient for real-world access.
The frame
The headline is that LSD now has positive pivotal Phase 3 data in depression, a multi-indication program, Breakthrough status in anxiety, and, in Ascend, a trial design built to meet the unblinding critique head-on. The market treated it as a landmark, and on the metric of registrational progress it is a significant step. But the two questions that determine whether it becomes a medicine are unchanged by a positive topline: whether the blinding design persuades the FDA that the effect is real rather than expectancy, and whether a daylong LSD session can be delivered at a scale and cost a health system will pay for. The readout answered neither. It simply made them the only questions left that matter.
For a sector that spent years with psilocybin and MDMA as its lead candidates, a late-stage program built on LSD, the oldest psychedelic of them all, reformulated and pushed through a rigorous registrational machine by the rebranded Definium, is the kind of result that redraws the map. The next markers are the anxiety readouts later this year and the full Emerge dataset. Until then, the topline is a genuine milestone wearing a very familiar molecule, and the hard questions sit exactly where they were.